Studying the Hypoglycemic Activity of Combinations of Maloben with Synthetic Antidiabetic Drugs on a Streptozocin Model of Diabetes Mellitus

In this paper, we study the hypoglycemic activity of the 4,4'-(propanediamido)dibenzoate sodium (maloben) pharmaceutical substance in combination with metformin, an antidiabetic drug of the biguanide class, and empagliflozin, an inhibitor of sodium-dependent glucose transporter type 2 (SGLT2) in the kidneys, in the setting of a streptozocin model of diabetes mellitus in combination with a high-fat diet in laboratory outbred male rats. The use of a high-fat diet makes it possible to simulate the state of prediabetes and increase the effectiveness of streptozocin administration. Streptozocin increases the level of glucose in the blood and urine of animals, as well as that of diuresis, which indicates the development of a pathology similar to actual type 2 diabetes mellitus. As part of the study, the dynamics of changes in glucose in the blood and urine, daily diuresis, and body weight of animals were analyzed.